Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johanna Campbell

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Oncotarget|February 15, 2011
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapyBhavya Rao, Ingeborg M M van Leeuwen, Maureen Higgins, et al.
Molecular Cancer Therapeutics|February 19, 2013
Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2Ingeborg M M van Leeuwen, Maureen Higgins, Johanna Campbell, et al.
Cell Cycle (Georgetown, Tex.)|April 15, 2011
Mechanism-specific signatures for small-molecule p53 activatorsIngeborg M M van Leeuwen, Maureen Higgins, Johanna Campbell, et al.
Oncotarget|June 2, 2015
Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cellsMarijke C C Sachweh, William C Stafford, Catherine J Drummond, et al.
Journal of Medicinal Chemistry|May 8, 2009
Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activityFederico Medda, Rupert J M Russell, Maureen Higgins, et al.
Bioorganic & Medicinal Chemistry|February 7, 2012
Synthesis and biological characterisation of sirtuin inhibitors based on the tenovinsAnna R McCarthy, Lisa Pirrie, Jonathan J Hollick, et al.
Molecular Cancer Therapeutics|January 17, 2013
Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent mannerAnna R McCarthy, Marijke C C Sachweh, Maureen Higgins, et al.
Cell Cycle (Georgetown, Tex.)|October 31, 2008
Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screenOliver D Staples, Jonathan J Hollick, Johanna Campbell, et al.
Cancer Cell|May 6, 2008
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activatorSonia Lain, Jonathan J Hollick, Johanna Campbell, et al.
Nature Communications|May 24, 2018
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockageMarcus J G W Ladds, Ingeborg M M van Leeuwen, Catherine J Drummond, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Oncotarget|February 15, 2011
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapyBhavya Rao, Ingeborg M M van Leeuwen, Maureen Higgins, et al.
Molecular Cancer Therapeutics|February 19, 2013
Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2Ingeborg M M van Leeuwen, Maureen Higgins, Johanna Campbell, et al.
Cell Cycle (Georgetown, Tex.)|April 15, 2011
Mechanism-specific signatures for small-molecule p53 activatorsIngeborg M M van Leeuwen, Maureen Higgins, Johanna Campbell, et al.
Oncotarget|June 2, 2015
Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cellsMarijke C C Sachweh, William C Stafford, Catherine J Drummond, et al.
Journal of Medicinal Chemistry|May 8, 2009
Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activityFederico Medda, Rupert J M Russell, Maureen Higgins, et al.
Bioorganic & Medicinal Chemistry|February 7, 2012
Synthesis and biological characterisation of sirtuin inhibitors based on the tenovinsAnna R McCarthy, Lisa Pirrie, Jonathan J Hollick, et al.
Molecular Cancer Therapeutics|January 17, 2013
Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent mannerAnna R McCarthy, Marijke C C Sachweh, Maureen Higgins, et al.
Cell Cycle (Georgetown, Tex.)|October 31, 2008
Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screenOliver D Staples, Jonathan J Hollick, Johanna Campbell, et al.
Cancer Cell|May 6, 2008
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activatorSonia Lain, Jonathan J Hollick, Johanna Campbell, et al.
Nature Communications|May 24, 2018
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockageMarcus J G W Ladds, Ingeborg M M van Leeuwen, Catherine J Drummond, et al.
Pageof 2